CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 644 enrolled
Drug / intervention
Zagreb +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01680016
NCT01680016Phase 3Completed

A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults

Novartis Vaccines·interventional·Posted Sep 6, 2012·Updated May 20, 2014

In Brief

A Phase 3 clinical trial evaluating Zagreb and Essen for Rabies. Completed, enrolled 644 participants across 1 site.

Detailed Summary

This study was designed to evaluate the safety and immunogenicity of two simulated postexposure rabies vaccination schedules (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese children and older adults.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRabies
CountriesChina
Collaborators--

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 6, 2012
Enrollment StartSep 1, 2012
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.8 years ago

Interventions

Zagrebbiological

Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22

Essenbiological

Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29